Last reviewed · How we verify
NCT04025255
The Memory and Cognitive Performance Study
NA trial testing Braini in Cognitive Function in 74 participants. Completed in 30 April 2020.
9 April 2020
Quick facts
| Lead sponsor | Vita Naturel, LLC |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 74 |
| Start date | 1 October 2019 |
| Primary completion | 9 April 2020 |
| Estimated completion | 30 April 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Braini
- Placebo
Conditions studied
- Cognitive Function — all drugs for Cognitive Function →
- Memory — all drugs for Memory →
- Brain Health — all drugs for Brain Health →
Sponsor
Vita Naturel, LLC
Who can join
Adults 18 to 80, any sex, with Cognitive Function or Memory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this study is to evaluate the impact of a novel, neuro-protective and neuro-restorative dietary supplement (Braini®) on standardized memory and cognitive performance parameters. The principal active ingredients in the Braini® supplement have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) in 2018, with no adverse events reported to the FDA. A 28-day randomized, double-blinded, placebo-controlled dietary supplement study will be conducted with a cohort of younger and a cohort of colder adults to achieve the purpose of this study. The research team hypothesizes that Braini® will improve standardized performance scores measured by CNS Vital Signs standard memory and cognitive performance assays more effectively than placebo.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Randomized, Placebo-Controlled Clinical Trial of a Novel Dietary Supplement on Standardized CNS Vital Signs Cognitive Performance Parameters in Adults.
Lanou AJ, Mast AC, Hill BD, Kim SS, et al · · 2023 · cited 2× · PMID 36856456 · DOI 10.1089/jicm.2022.0543
Verify or expand the search:
- PubMed search for NCT04025255
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Function
Currently open trials in the same condition.
- NCT07586696 — Effects of Exercise Board Games on Cognitive Function in Older Adults · NA · active not recruiting
- NCT07245784 — Radicle Clarity™ RBB: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Hea · NA · recruiting
- NCT07103343 — MOVI-OLE! [Open Learning Environments] · NA · active not recruiting
- NCT07312435 — B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy. · NA · recruiting
- NCT07139210 — EFFECT OF PERCEPTUAL-MOTOR TRAINING ON COGNITIVE FUNCTIONS, MOTOR ABILITIES AND QUALITY OF LIFE IN CHILDREN WITH ATTENTI · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04025255 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vita Naturel, LLC
- Last refreshed: 21 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04025255.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing